ATRIUM THERAPEUTICS INC (RNA) Stock Price & Overview
NASDAQ:RNA • US05370A1088
The current stock price of RNA is 15.48 USD. Today RNA is down by -6.41%. In the past month the price decreased by -77.26%. In the past year, price decreased by -45.39%.
RNA Key Statistics
- Market Cap
- 2.395B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.18
- Dividend Yield
- N/A
RNA Stock Performance
RNA Stock Chart
RNA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to RNA. When comparing the yearly performance of all stocks, RNA is a bad performer in the overall market: 96.83% of all stocks are doing better.
RNA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RNA. RNA has a great financial health rating, but its profitability evaluates not so good.
RNA Earnings
On November 10, 2025 RNA reported an EPS of -1.27 and a revenue of 12.47M. The company missed EPS expectations (-14.2% surprise) and beat revenue expectations (490.11% surprise).
RNA Forecast & Estimates
18 analysts have analysed RNA and the average price target is 74.07 USD. This implies a price increase of 378.47% is expected in the next year compared to the current price of 15.48.
For the next year, analysts expect an EPS growth of -57.4% and a revenue growth 134.19% for RNA
RNA Groups
Sector & Classification
RNA Financial Highlights
Over the last trailing twelve months RNA reported a non-GAAP Earnings per Share(EPS) of -4.18. The EPS decreased by -45.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.76% | ||
| ROE | -29.15% | ||
| Debt/Equity | 0 |
RNA Ownership
RNA Latest News, Press Relases and Analysis
RNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.83 | 417.437B | ||
| AMGN | AMGEN INC | 16.11 | 204.229B | ||
| GILD | GILEAD SCIENCES INC | 16.17 | 183.894B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.53 | 121.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 83.255B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.15 | 43.24B | ||
| INSM | INSMED INC | N/A | 31.965B | ||
| NTRA | NATERA INC | N/A | 28.775B | ||
| BIIB | BIOGEN INC | 12.36 | 27.876B | ||
| MRNA | MODERNA INC | N/A | 22.581B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 21.486B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.053B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.749B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RNA
Company Profile
Avidity Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California. The company went IPO on 2020-06-12. Avidity Biosciences, Inc. is a biopharmaceutical company. The firm is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
Company Info
ATRIUM THERAPEUTICS INC
3020 Callan Road
San Diego CALIFORNIA 92037 US
CEO: Sarah Boyce
Employees: 391
Phone: 18584017900
ATRIUM THERAPEUTICS INC / RNA FAQ
Can you describe the business of ATRIUM THERAPEUTICS INC?
Avidity Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California. The company went IPO on 2020-06-12. Avidity Biosciences, Inc. is a biopharmaceutical company. The firm is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
What is the stock price of ATRIUM THERAPEUTICS INC today?
The current stock price of RNA is 15.48 USD. The price decreased by -6.41% in the last trading session.
What is the dividend status of ATRIUM THERAPEUTICS INC?
RNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of RNA stock?
RNA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does ATRIUM THERAPEUTICS INC belong to?
ATRIUM THERAPEUTICS INC (RNA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for RNA stock?
ATRIUM THERAPEUTICS INC (RNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.18).